MC2 Therapeutics is a mature biotech company developing novel treatment paradigms within immunology and inflammation (“I&I”).
Our cross-silo thinking, combining deep knowledge of immunology with a multi-disciplinary approach spanning all fields of science and product development to market access provide an enhanced ability to identify new treatment opportunities that are truly differentiated.
Our two Ph2 stage first-in-class and novel mode of action drug candidates with multiple indication potential (“I&I pipeline in a product”) are:
MC2-32: Oral HSP90 Inhibitor with unique pharmacological profile targeting multiple pro-inflammatory pathways and relevant immune responses while uniquely demonstrating a favorable safety profile.
MC2-25: Iso-cyanate Scavenger addressing non-enzymatic posttranslational protein and amino acid modification (carbamylation) in the skin by iso-cyanate, a dissociation product of urea.
We are currently pursuing indications where there are none or very limited approved treatment options, including oral MC2-32 for Hidradenitis Suppurativa (Ph2a completed) and MC2-25 for Chronic Kidney Disease-associated Pruritus (Ph2 enrollment completed, n=111) and MC2-25 for Vulvar Lichen Sclerosus (Ph2a ongoing).
Our operational excellence integrates our commercial experience and knowledge built from bringing MC2 Therapeutics’ first approved drug Wynzora® Cream for plaque psoriasis to the market in the US and Europe as part of our global partnering strategy on Wynzora®.
We integrate a high-performance networked team of experts to maximize execution power and allowing us to identify the optimal strategic pathways to broaden our business and build momentum.
Read more about our pipeline here.
Read more about Wynzora® Cream drug for treatment of plaque psoriasis in adults here.